BioCentury | May 7, 2012
Company News

Bio-Reference Laboratories sales and marketing update

...Bio-Reference's GenPath Women's Health Laboratory unit launched its GenCerv HPV assay in the U.S to quantify...
BioCentury | Jan 22, 2007
Strategy

Offshore shopping

...a standard pre-screen, so patients with specific mutations will be easy to identify. Aveo (formerly GenPath Pharmaceuticals Inc....
BioCentury | Nov 7, 2005
Tools & Techniques

Better cancer mice

...Last week's deal is Aveo's second with MRK (Whitehouse Station, N.J.). In 2003, AVEO, then GenPath Pharmaceuticals Inc....
BioCentury | May 2, 2005
Finance

MPM's portfolio

...Cancer; Functional genomics Germany Series B 3/15/04 $6.1 Steven St. Peter, Michael Steinmetz Aveo (formerly GenPath...
BioCentury | Jun 7, 2004
Strategy

Venture portfolio balancing

...play TransForm Pharmaceuticals Inc. (Lexington, Mass.), memory company Sention Inc. (Providence, R.I.) and anti-infectives company GenPath Pharmaceuticals Inc....
BioCentury | Mar 29, 2004
Strategy

All that Jazz . . .

...Management; Care Capital; MedImmune Ventures; MPM Capital; Prospect Venture Partners Note: Sold IPO on 3/17/04 GenPath...
BioCentury | Nov 24, 2003
Company News

GenPath, Merck deal

...will have an exclusive option to license exclusive development and marketing rights to resulting targets. GenPath...
...receive an upfront payment and annual research funding, and is eligible for milestones and royalties. GenPath...
...could receive more than $100 million in payments, excluding royalties, if multiple products are commercialized. GenPath Pharmaceuticals Inc....
BioCentury | Nov 17, 2003
Politics, Policy & Law

Infinite innuendo

...compensation for any work) of any current NIH employee" for Infinity, as well as for GenPath Pharmaceuticals Inc....
BioCentury | Oct 6, 2003
Company News

GenPath board of directors update

GenPath Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer Appointed: Muzammil Mansuri, a venture partner at Flagship Ventures; and Robert Higgins, managing general partner of Highland Capital Partners WIR Staff cancer...
BioCentury | Oct 6, 2003
Finance

Ebb & Flow

...the global business development and licensing group at Novartis (SWX:NOVN; NVS). Private rounds Cancer play GenPath...
...Greylock; Kenneth Weg, former vice chairman of Bristol-Myers (BMY); and life science VC Grant Heidrich. GenPath...
Items per page:
1 - 10 of 22
BioCentury | May 7, 2012
Company News

Bio-Reference Laboratories sales and marketing update

...Bio-Reference's GenPath Women's Health Laboratory unit launched its GenCerv HPV assay in the U.S to quantify...
BioCentury | Jan 22, 2007
Strategy

Offshore shopping

...a standard pre-screen, so patients with specific mutations will be easy to identify. Aveo (formerly GenPath Pharmaceuticals Inc....
BioCentury | Nov 7, 2005
Tools & Techniques

Better cancer mice

...Last week's deal is Aveo's second with MRK (Whitehouse Station, N.J.). In 2003, AVEO, then GenPath Pharmaceuticals Inc....
BioCentury | May 2, 2005
Finance

MPM's portfolio

...Cancer; Functional genomics Germany Series B 3/15/04 $6.1 Steven St. Peter, Michael Steinmetz Aveo (formerly GenPath...
BioCentury | Jun 7, 2004
Strategy

Venture portfolio balancing

...play TransForm Pharmaceuticals Inc. (Lexington, Mass.), memory company Sention Inc. (Providence, R.I.) and anti-infectives company GenPath Pharmaceuticals Inc....
BioCentury | Mar 29, 2004
Strategy

All that Jazz . . .

...Management; Care Capital; MedImmune Ventures; MPM Capital; Prospect Venture Partners Note: Sold IPO on 3/17/04 GenPath...
BioCentury | Nov 24, 2003
Company News

GenPath, Merck deal

...will have an exclusive option to license exclusive development and marketing rights to resulting targets. GenPath...
...receive an upfront payment and annual research funding, and is eligible for milestones and royalties. GenPath...
...could receive more than $100 million in payments, excluding royalties, if multiple products are commercialized. GenPath Pharmaceuticals Inc....
BioCentury | Nov 17, 2003
Politics, Policy & Law

Infinite innuendo

...compensation for any work) of any current NIH employee" for Infinity, as well as for GenPath Pharmaceuticals Inc....
BioCentury | Oct 6, 2003
Company News

GenPath board of directors update

GenPath Pharmaceuticals Inc. , Cambridge, Mass. Business: Cancer Appointed: Muzammil Mansuri, a venture partner at Flagship Ventures; and Robert Higgins, managing general partner of Highland Capital Partners WIR Staff cancer...
BioCentury | Oct 6, 2003
Finance

Ebb & Flow

...the global business development and licensing group at Novartis (SWX:NOVN; NVS). Private rounds Cancer play GenPath...
...Greylock; Kenneth Weg, former vice chairman of Bristol-Myers (BMY); and life science VC Grant Heidrich. GenPath...
Items per page:
1 - 10 of 22